GENOMICS PROFILING

贝勒医学院(BCM)丹·L·邓肯癌症中心(DLDCC)的基因组图谱共享资源(GPSR)利用贝勒医学院和德克萨斯儿童医院(TCH)可用的专业知识，利用尖端基因组和转录组技术为DLDCC成员提供一整套服务。GPSR核心结合了尖端技术，为转录和基因组图谱提供最先进的基于微阵列和下一代测序的优质服务和分析。该资源帮助DLDCC研究人员利用微阵列技术、下一代测序技术、良好的实验设计以及数据管理和数据分析资源。我们将于2009年10月开始向DLDCC成员提供下一代测序技术(LlLumina Genome Analyzer II)。 许多DLDCC研究人员对利用最先进的技术，如微阵列表达谱分析，试图剖析与癌症相关的因果关系感兴趣。对于个别实验室来说，建立微阵列能力的成本和专业水平令人望而却步(初始设备购买成本可能在25万至75万美元之间)，需要像GPSR这样的设施。 在过去的十年里，我们见证了与基因组测序工作的成果直接相关的研究的重大进步。这些成果为研究包括癌症在内的复杂疾病的研究人员带来了希望。在癌症中，识别病因的复杂障碍不仅包括染色体异常(大体和亚微观)，而且还包括具有异常表达谱的一个或几个基因的变化，甚至是具有扰动表达的成百上千个基因的变化。这可能导致癌症基因表达谱的混乱，很难进行分类 这对试图阐明癌症的因果关系的研究人员提出了挑战。GPSR致力于为DLDCC成员提供坚实的专业知识基础，以便理解通过这项技术产生的大型数据集。

The Genomic Profiling Shared Resource (GPSR) of the Dan L. Duncan Cancer Center (DLDCC) at Baylor College of Medicine (BCM) utilizes the expertise available at both BCM and Texas Children's Hospital (TCH) to offer a comprehensive suite of services using cutting edge genomic and transcriptomic technologies to DLDCC members. The GPSR core combines cutting edge technologies to provide state-of-the-art quality microarray-based and next generation sequencing-based services and analyses for both transcriptional and genomic profiling. This resource provides assistance to DLDCC researchers in utilizing microarray technology, next generation sequencing technology, good experimental design, and data management and data analysis resources. We will begin offering next generation sequencing technology (lllumina Genome Analyzer II) to DLDCC members in October 2009. Many DLDCC researchers are interested in utilizing state-of-the-art technologies such as microarray expression profiling to attempt to dissect the causes and effects associated with cancer. For individual laboratories, the costs and levels of expertise associated with establishing a microarray capability is prohibitive (initial equipment purchases can cost between $250,000 and $750,000) requiring a facility like the GPSR. Within the past decade we have witnessed significant advancements in research that are directly associated with the output of the genome sequencing endeavor. The results of these achievements provide hope to investigators researching complex disease including cancer. In cancer, complex barriers to the identification of cause include not only chromosomal abnormalities (gross and submicroscopic) but alterations in one or several genes having aberrant expression profiles or even hundreds to thousands of genes with perturbed expression. This can result in a mishmash of cancer gene expression profiles that is difficult to sort through presenting a challenge to researchers attempting to elucidate the cause and effect of cancer. The GPSR works to provide DLDCC members a solid base of expertise to tap in order to make sense of the large data sets generated with this technology.